Stock ME 23ANDME HOLDING CO.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases 23andMe Holding Co.

Equities

ME

US90138Q1085

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-09 pm EDT 		5-day change 1st Jan Change
0.51 USD +5.66% Intraday chart for 23andMe Holding Co. +1.07% -44.17%
Apr. 24 23andMe Holding Co. to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology Annual Meeting CI
Apr. 23 Petros, Lemonaid Health Collaborate to Expand Stendra Availability MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Potter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach Case
BU
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GL
23andMe announces CEO’s intention to pursue a potential take-private
GL
23andMe announces CEO’s intention to pursue a potential take-private
AQ
23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
GL
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
GL
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
AQ
23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago
GL
23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago
AQ
23andMe Launches New Genetic Reports on Common Forms of Cancer
GL
23andMe Launches New Genetic Reports on Common Forms of Cancer
AQ
23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
GL
23andMe Reports Third Quarter Fiscal 2024 Financial Results
GL
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
GL
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
AQ
23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay
GL
23andMe to Report FY2024 Third Quarter Financial Results
GL
23andMe to Report FY2024 Third Quarter Financial Results
AQ
23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts
GL
23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ME Stock
  4. News 23andMe Holding Co.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW